Pfizer (PFE) & SCYNEXIS (SCYX) Head-To-Head Comparison
Pfizer (NYSE: PFE) and SCYNEXIS (NASDAQ:SCYX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Pfizer pays an annual dividend of $1.28 per share and has a dividend yield of 3.5%. SCYNEXIS does not pay a dividend. Pfizer pays out 78.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 8 consecutive years.
This is a summary of current recommendations for Pfizer and SCYNEXIS, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pfizer presently has a consensus target price of $38.73, suggesting a potential upside of 6.21%. SCYNEXIS has a consensus target price of $9.50, suggesting a potential upside of 382.23%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Pfizer.
Valuation and Earnings
This table compares Pfizer and SCYNEXIS’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pfizer||$52.82 billion||4.12||$7.22 billion||$1.63||22.37|
Pfizer has higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
69.7% of Pfizer shares are held by institutional investors. Comparatively, 30.9% of SCYNEXIS shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 4.0% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Pfizer and SCYNEXIS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Pfizer has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
Pfizer beats SCYNEXIS on 12 of the 17 factors compared between the two stocks.
Pfizer Company Profile
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.